Illegal Activity
none
Blackmail
none
Date
April 2014
Document Type
article
Model
gemini-2.0-flash-001
Processed
2026-02-07T18:43
Summary
The article discusses the advancements and challenges in using CRISPR-Cas9 for therapeutics, focusing on Editas and its competitors. It highlights the financial investments, patent battles, and the need for further development before widespread clinical application.
Metadata
- Subject
- CRISPR-Cas9 Therapeutics
- Sender
- —
- Recipients
- —
- Document ID
- SDNY_GM_00248702
- Date
- April 2014
Relationships 5
| Entity 1 | Relationship | Entity 2 | Description |
|---|---|---|---|
| Editas | co-founder | Feng Zhang | Feng Zhang is a co-founder of Editas. |
| Doudna | licensed to | Caribou | Doudna's work is licensed to Caribou. |
| Caribou | licensed to | Intellia | Caribou has licensed use of its technology for human therapies to Intellia. |
| Emmanuelle Charpentier | licensed to | CRISPR | The work of Emmanuelle Charpentier is licensed to CRISPR. |
| Doudna | co-founder | Editas | Doudna was an Editas co-founder, but later cut ties with the company. |
Notable Quotes 3
our knowledge of the genome is just at a fundamentally different place
isn't trying to reinvent the wheel
a critical challenge in this field, there's no question about that
Financial Information
Amounts:$450 million$120 million
Transactions:
- Editas raised $120 million to bring several programs to clinical testing.
Media & Journalist References
- MIT Technology Review reported that Doudna cut ties with Editas.
Public Knowledge
- Context
- The progress of CRISPR-Cas9 technology is of interest to the public and media.
- Media Worthy
- Yes
Legal Compliance
- Patent battle between Editas and Doudna's group at UC Berkeley.
Raw Analysis JSON
click to expand
Themes
Business dealingsLegal matters/litigation
Organizations 11
EditasUC BerkeleyU.S. Patent and Trademark OfficeBroad Institute of MITHarvardCaribouIntelliaCRISPRMIT Technology ReviewModemaWall Street
Locations 1
US
Text Analysis
- Tone
- Informative
- Purpose
- To discuss the progress and challenges of CRISPR-Cas9 technology for therapeutics, focusing on Editas and its competitors.
- Significance
- The article highlights the potential of CRISPR-Cas9 technology and the financial investments being made in the field, while also acknowledging the challenges and patent battles involved.
File Info
- File Name
- EFTA01447777.txt
- Dataset
- dataset_10
- Type
- Text
- Model
- gemini-2.0-flash-001
- Processed
- 2026-02-07T18:43:53.650275
- DOJ Source
- View on DOJ